Compare VOD & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOD | KVUE |
|---|---|---|
| Founded | 1984 | 2022 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Specialty Chemicals |
| Sector | Telecommunications | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 33.1B |
| IPO Year | 1988 | 2023 |
| Metric | VOD | KVUE |
|---|---|---|
| Price | $13.32 | $17.28 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 12 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 3.7M | ★ 32.7M |
| Earning Date | 05-12-2026 | 02-05-2026 |
| Dividend Yield | 3.68% | ★ 4.81% |
| EPS Growth | N/A | ★ 35.31 |
| EPS | N/A | ★ 0.75 |
| Revenue | ★ $45,501,583,954.00 | $15,006,000,000.00 |
| Revenue This Year | $11.65 | N/A |
| Revenue Next Year | $2.80 | $2.81 |
| P/E Ratio | ★ N/A | $23.07 |
| Revenue Growth | ★ 4.79 | N/A |
| 52 Week Low | $8.00 | $14.02 |
| 52 Week High | $13.30 | $25.17 |
| Indicator | VOD | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 74.13 | 58.77 |
| Support Level | $13.20 | $16.93 |
| Resistance Level | $13.30 | $17.31 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 95.73 | 66.96 |
Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK Vodafone merger with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.